https://hotcopper.com.au/threads/ann-agreement-with-c14-consulting-group.8180478/ Language of the Vectus ANN is a bit similar to BIT's one, but Vectus' ANN contains some more details. Hoy, not Michelle, will update the market with more clear details. Michelle appears to have copied and pasted some contents from Vectus ANN. Anyway, let's wait and see what unfold in 2025. My MSB has been showing spectacular price performance since Dec 2024. BIT holders would be delighted to see spectacular price performance in BIT's SP. Michelle and Hoy need to team with C14 to take Michelle's progress to the executed deal....in 2025. My MSB is now around $3.35/s, BIT's SHs would like to see BIT's SP at least $0.35/s. Best wishes!
"... 30 August 2024 Company Announcements Office Australian Securities Exchange Agreement with C14 Consulting Group Consistent with the Company’s strategic initiatives on commercialisation, Vectus has appointed C14 Consulting Group, LLC in an exclusive role to lead and manage the programme of potential licencing, joint venture or both of Vectus’ portfolio of patented small therapeutic molecules, including the human lead VB0004. Vectus’ drug library focuses on a range of anti-fibrotic applications aimed at cardio vascular disease, a significant unmet need. Specifically, VB0004, A32, A79 target reversal of disease in the heart, lung, kidney and liver. VB0004 has successfully undergone human Phase Ia trials and more recently Phase Ib human trials, with no adverse events recorded. Based in the USA, C14 is a highly regarded consultancy with a global capability. Led by Martina Molsbergen (Chief Executive Officer), the company has an enviable track record of securing licence agreements, joint ventures and commercialisation of pharmaceutical patented assets with all levels of pharma from large scale to biotech companies that specialise in orphan and targeted applications. C14 will now be managing existing discussions with, and expanding the outreach to, potential pharmaceutical partners. C14 has demonstrated that it has long standing relationships with a broad cross section of pharmaceutical companies and a detailed knowledge of the indications and market segments on which each of these companies are currently focusing. Providing for a management fee and an outcome-based success component, the agreement aligns the interests of the parties achieving one or more commercial outcomes. C14 business model is predicated on a broad analysis of the client’s technologies and typically engages with a client when there is a belief in the potential of the technology to be commercialised.
Ms Martina Molsbergen, Chief Executive Officer of the licencing firm in the USA, C14 Consulting Group commented: “C14 has a long track record in helping companies such as Vectus to advance towards the commercialisation of novel therapies. From our preliminary review of VB0004 and associated drug library, we have realised the compelling research that has been conducted thus far and the potential to be taken up by pharma in the exciting space of fibrosis remediation.” Dr Ron Shnier, Vectus Non-Executive Chairman said: “We are pleased to be partnering with C14, one of the world’s leading consultancies in pharmaceutical transactions. As previously reported, Vectus is concentrating its activities on achieving licencing or partnerships with its patented anti-fibrotic portfolio.” Vectus Biosystems Limited Dr Ron Shnier Chairman "
BIT Price at posting:
1.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)